GlassScriptPhysician profile
Jeffrey Alan Culp
NPI 1023156734
$3,793.27
in general payments reported to CMS, 2019-2025
21 companies · $1,556 in 2025
The $1,556 reported for 2025 was more than what a typical Allergy & Immunology (Internal Medicine) provider received nationally (typical 2025 total: $681).
See the full distribution for Allergy & Immunology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $290 · 2021: $166 · 2022: $356 · 2023: $915 · 2024: $511 · 2025: $1,556.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,948 · Education: $34.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,947.95 |
| Education | $34.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $1,131.56 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $707.89 | 2019-2025 | Fasenra, Tezspire, Airsupra |
| Glaxosmithkline, LLC. | $649.11 | 2019-2025 | Nucala, Arexvy, Trelegy Ellipta |
| Ars Pharmaceuticals Operations, INC. | $230.92 | 2025 | Neffy |
| Amgen INC. | $197.48 | 2022-2025 | Tezspire, Evenity |
| Novartis Pharmaceuticals Corporation | $167.98 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $141.46 | 2019-2022 | |
| Grifols USA, LLC | $124.37 | 2023-2025 | Xembify |
| Csl Behring | $91.62 | 2019-2023 | Hizentra |
| Biocryst US Sales Co., LLC | $53.46 | 2023-2024 | Orladeyo |
| Lilly USA, LLC | $43.79 | 2025 | Ebglyss |
| Genentech USA, INC. | $43.76 | 2019-2025 | Xolair |
| Kaleo, INC. | $43.63 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $35.16 | 2023 | Cuvitru |
| Alk-Abello, INC | $33.08 | 2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $22.06 | 2019 | |
| Paratek Pharmaceuticals, INC. | $19.87 | 2025 | Xhance |
| Optinose US, INC. | $15.11 | 2025 | |
| Stryker Corporation | $14.96 | 2025 | Scopis Ent |
| Teva Pharmaceuticals USA, INC. | $13.57 | 2019 | |
| Mylan Specialty L.P. | $12.43 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Culp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.